Volume 11, Number 9—September 2005
Dispatch
Perinatal Group B Streptococcal Disease Prevention, Minnesota
Craig A. Morin*
, Karen White*, Anne Schuchat†, Richard N. Danila*, and Ruth Lynfield*
, Karen White*, Anne Schuchat†, Richard N. Danila*, and Ruth Lynfield*
Table 2
Change in group B streptococci (GBS) screening characteristics among prenatal care providers reporting a screening-based approach, Minnesota, 1998 and 2002
| Characteristic | Obstetricians |
Midwives |
Family practitioners |
|||
|---|---|---|---|---|---|---|
| 1998, n (%) (N = 45) | 2002, n (%) (N = 170) | 1998, n (%) (N = 13) | 2002, n (%) (N = 70) | 1998, n (%) (N = 84) | 2002, n (%) (N = 53) | |
| Vaginal/rectal screening | 41 (91) | 153 (90) | 6 (46) | 68 (97)* | 61 (73) | 41 (77) |
| Screening at 35–37 weeks of gestation | 42 (93) | 152 (89) | 10 (77) | 62 (89) | 77 (92) | 44 (83) |
| Use selective broth† | 12 (27) | 122 (72)‡ | 2 (15) | 28 (40) | 34 (40) | 21 (40) |
| Penicillin first IAP choice§ | 35 (78) | 138 (81) | 7 (54) | 60 (86)¶ | 32 (38) | 27 (51) |
*p<0.001, use of vaginal/rectal screening from 1998 to 2002.
†Prenatal care providers were asked if their laboratory used selective broth to isolate GBS.
‡p<0.001, use of selective broth from 1998 to 2002.
§IAP, intrapartum antimicrobial prophylaxis.
¶p<0.01, penicillin as first choice for IAP from 1998 to 2002.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.